The chemical class known as CNK2 Inhibitors includes a diverse array of compounds designed to inhibit the function of CNK2, a key scaffold protein involved in numerous cellular signaling pathways, particularly the MAPK (Mitogen-Activated Protein Kinase) pathways. CNK2 inhibitors are developed to modulate the activity of CNK2, which is essential in mediating cellular responses within these pathways. The primary mechanism of these inhibitors is to target essential components of the MAPK signaling pathways, such as MEK1/2, JNK, and p38 MAP kinase. By inhibiting these key elements, CNK2 inhibitors disrupt the MAPK pathway, consequently affecting the scaffolding function of CNK2. This leads to significant alterations in the typical signaling processes where CNK2 plays a pivotal role.
CNK2 inhibitors consist of small molecules targeting specific kinases within the MAPK pathways. These inhibitors bind with high specificity to their targets, effectively inhibiting kinase activity and thereby interfering with downstream signaling events. Some inhibitors in this class are selective for MEK1/2, which are crucial in the MAPK/ERK pathway, while others focus on JNK or p38 MAPK, integral components of the MAPK pathways. By influencing these kinases, CNK2 inhibitors affect CNK2-mediated cellular responses, particularly in pathways related to signal transduction and cell proliferation. Moreover, certain compounds in this class have the capacity to inhibit multiple kinases within the MAPK pathway, offering a more extensive approach in disrupting the signaling pathways involving CNK2. These inhibitors are characterized by their ability to perturb the normal functions of the MAPK pathways, which are essential for a variety of cellular processes, including cell growth, differentiation, and survival. In summary, CNK2 inhibitors represent a significant class of compounds capable of influencing critical cellular signaling pathways. Their impact on the MAPK pathways through the inhibition of key kinases highlights their role in cellular signaling and regulation. The ability of these inhibitors to modulate CNK2 function is key to understanding the complex interplay between scaffold proteins like CNK2 and the signaling pathways they regulate. As such, CNK2 inhibitors are invaluable in studying the biological functions of CNK2 and its involvement in diverse cellular processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 blocks the activation of MEK, which is key in the MAPK/ERK pathway. This action could possibly inhibit CNKSR2's function in signal transduction. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, part of the MAPK pathway. By targeting JNK, it could possibly inhibit CNKSR2 through its effects on the MAPK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase. This inhibition could possibly inhibit CNKSR2's role in MAPK-mediated cellular responses. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple kinases within the MAPK pathway. Its broad kinase inhibition could possibly inhibit CNKSR2's involvement in these pathways. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor, blocks the MAPK/ERK pathway. This action could possibly inhibit CNKSR2's role in this signaling cascade. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib inhibits the MAPK/ERK pathway by targeting MEK. This could possibly inhibit CNKSR2's involvement in downstream signaling events. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
BIRB 796 inhibits p38 MAPK. Its action could possibly inhibit CNKSR2's role in signaling processes within the MAPK pathway. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
VX-745 is a p38 MAPK inhibitor. Its inhibition of p38 MAPK could possibly inhibit CNKSR2's role in mediating cellular responses within the MAPK pathway. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $370.00 | 5 | |
SCH772984 is an ERK inhibitor. It could possibly inhibit CNKSR2 by disrupting signal transduction processes in the MAPK pathway. | ||||||